Burning Rock Biotech Limited's SEC filings document its status as a foreign private issuer with American depositary shares and its NGS-based precision oncology business. Form 6-K reports furnish quarterly and annual financial results, business updates for therapy selection, MRD, early detection and pharma services, and exhibits incorporated by reference into Form F-3 registration statements.
The company's disclosure record also includes annual Form 20-F reporting with audited consolidated financial statements. These filings address operating results, segment revenue, research and development spending, ADS-related matters, governance and risk factors for a China-based cancer diagnostics issuer.
Burning Rock Biotech Ltd Schedule 13G/A (Amendment No. 4) reports that Kynam Capital Management, LP (with related filers) beneficially owns 1,227,555 ADSs, representing 13.97% of the class. The filing lists shared voting and dispositive power of 1,227,555 ADSs for Kynam entities and Yue Tang. The signatures are dated 05/15/2026.
Burning Rock Biotech Ltd. amendment to a Schedule 13G/A reports beneficial ownership disclosures by CRCM-related reporting persons, showing shared dispositive power over certain American Depository Shares (each ADS = ten Class A Ordinary Shares). The cover rows list holdings of 275,025 shares and 282,097 shares, representing 3.1% and 3.2% of Class A Ordinary Shares, respectively, based on 88,138,581 shares outstanding as of March 31, 2026.
Burning Rock Biotech Limited reports 2025 consolidated revenue of RMB539.6 million and a net loss of RMB55.3 million (about US$7.9 million), a much smaller loss than in 2023 and 2024.
The company operates its China business mainly through a variable interest entity structure and faces extensive PRC regulatory, data security, cybersecurity and overseas-listing risks, as well as uncertainties around cash transfers, foreign exchange controls and enforceability of VIE contracts. Cash and cash equivalents totaled RMB478.4 million (about US$68.4 million) at year-end 2025.
Burning Rock Biotech Ltd director Han Yusheng bought 314,870 shares in an open-market purchase. The shares were acquired at a weighted average price of $17.36 per share, across multiple trades between $16.10 and $18.99. Following this transaction, he directly owns 17,672,676 shares, reflecting a significant ongoing stake in the company.
Burning Rock Biotech Ltd director Deng Feng filed an initial Form 3 reporting indirect holdings of the company’s Ordinary Shares. The filing shows positions held through Northern Light Venture Fund III, L.P., Northern Light Strategic Fund III, L.P., and Northern Light Partners Fund III, L.P.
These Cayman Islands partnerships are managed by Northern Light Venture Capital III, Ltd., where Deng Feng serves as director and makes investment decisions. He disclaims beneficial ownership of the reported securities for Section 16 purposes, except to the extent of any pecuniary interest.
Burning Rock Biotech Ltd director Wendy W. Hayes filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing establishes her status as a director and indicates that no insider transactions or derivative positions are reported in this submission.
Burning Rock Biotech Ltd director Han Yusheng has filed an initial ownership report showing a substantial equity stake and multiple option awards. The filing lists direct ownership of 17,357,806 Ordinary Shares.
Han also holds several option grants over Ordinary Shares. These include 1,413,063 and 2,119,595 options with a $3.33 exercise price that vest only if the company’s valuation reaches $4 billion within seven years of the September 26, 2022 grant date and employment conditions are met. Additional grants of 706,532 and 1,059,797 options at the same exercise price require a $10 billion valuation target plus similar service conditions.
Further grants on April 30, 2023, April 30, 2024 and April 30, 2025 cover 236,023, 86,000 and 116,000 options at a $0.0002 exercise price, vesting in stages from 2025 through 2029 based on continued employment and minimum performance ratings. Each option gives the right to receive one Ordinary Share upon exercise.
Burning Rock Biotech Ltd director Zhang Zhihong filed an initial ownership report showing direct holdings of 1,061,990 Ordinary Shares and multiple option awards. These include options over 78,504 and 117,755 Ordinary Shares at an exercise price of $3.33 expiring on September 26, 2032, plus additional options over 51,469, 41,000, and 56,000 shares at an exercise price of $0.0002 expiring between 2033 and 2035. Several grants vest only if Burning Rock’s valuation and the director’s employment and performance conditions are met.
Burning Rock Biotech Ltd filed an initial Form 3 for Hu Xiaozhi, a Senior Director in Finance, detailing existing stock option holdings rather than new market trades. The options give the right to receive one ordinary share per option at exercise prices as low as $0.0002 and $3.33.
The footnotes show these awards vest only if strict conditions are met, including continued employment, annual performance ratings of at least 3.3%, and ambitious company valuation targets of $2 billion, $4 billion, or $10 billion within specified five- or seven-year periods from each grant date.
Burning Rock Biotech Ltd director Xu Licen Lisa filed an initial Form 3 reporting her ownership in the company. The filing shows she directly holds 22,718 Ordinary Shares following the reported position. This is a disclosure of existing holdings and does not reflect any recent share purchase or sale activity.